Author/Authors :
Ghanbari، Reza نويسنده Digestive Oncology Research Center Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Ghanbari, Reza , Mosakhani، Neda نويسنده Department of Pathology, Haartman Institute, Helsinki
University, Helsinki, Finland , , Asadi، Jahanbakhsh نويسنده Biochemistry and Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, IR Iran , , Nouraee، Nazila نويسنده , , Mowla، Seyed Javad نويسنده , , Yazdani، Yaghoub نويسنده Immunilogy Departmen, Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran , , Mohamadkhani، Ashraf نويسنده Digestive Disease Research Centre, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran , , Poustchi، Hossein نويسنده Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran Poustchi, Hossein , Knuutila، Sakari نويسنده Department of Pathology, Haartman Institute, Helsinki
University, Helsinki, Finland , , Malekzadeh، Reza نويسنده ,
Abstract :
Background: Colorectal cancer is one of the most commonly diagnosed cancers and cancer- related death worldwide. Identification of new specific biomarkers could be helpful to detection of this malignancy. Altered plasma microRNA expression has been identified in many cancers, including colorectal cancer.
Objectives: The main objective of this study was to identify the circulating microRNAs with the most expression changes in colorectal cancer patients compared with neoplasm free healthy individuals.
Materials and Methods: MicroRNA expression profiling was performed on plasma samples of 37 colorectal cancer patients and 8 normal subjects using microRNA microarray. Quantitative real-time reverse transcription polymerase chain reaction was used to validate the two selected altered microR NAs. Plasma samples from 61 colorectal cancer patients and 24 normal subjects were used in our validation study.
Results: In profiling study we found a panel of six plasma microRNAs with significant downregulation. MicroRNA-142-3p and microRNA-26a-5p were selected and validated by polymerase chain reaction. Our results demonstrated that expression levels of plasma microRNA-142-3p and microRNA-26a-5p were significantly downregulated in patients with colorectal cancer when compared to control group.
Conclusions: Our findings suggest that downregulation of plasma microRNA-142-3p and microRNA-26a-5p might serve as novel noninvasive biomarkers in the diagnosis of colorectal cancer, although more studies are needed to highlight the theoretical strengths.
